First, I thank colleagues for their support in securing tonight’s debate. If the past few months have taught us anything, it is that we are not safe until everyone is safe.
There is massive inequality in access to vaccines across the globe. As of last week, in high-income countries, 66.3 per cent of people had been vaccinated with at least one dose, but in low-income countries only 9 per cent of people had been.
Therefore, with omicron cases rising daily, it has never been more important to debate the need to end pharmaceutical monopolies of Covid-19 vaccines. To address the cost of vaccinating 70 per cent of the population in high-income countries would mean an increase of 0.8 per cent in healthcare spending; in low-income countries, an eye-watering 56.6 per cent increase would be needed. That money is simply not available.
In an excellent briefing, the People’s Vaccine Alliance noted that work has been going on to get a solution. It said that, in October 2020:
“South Africa and India submitted a joint proposal to the TRIPS (Trade Related Aspects of Intellectual Property Rights) Council at the World Trade Organisation (WTO), titled ‘Waiver from certain provisions of the TRIPS agreement for the prevention, containment and treatment of COVID-19’. The UK Government rejected the text on the Waiver at the TRIPS Council meeting”—
in October of that year—
“saying that it was not necessary whilst also stating that existing measures to overcome Intellectual Property (IP) barriers would suffice.
The Waiver would allow all WTO members to choose to not grant or not enforce patents and other IP related to COVID-19 drugs, vaccines, diagnostics and other technologies until widespread vaccination is in place globally, and the majority of the world’s population has developed immunity ... The proposed waiver would be applicable only to COVID-19 health technologies.”
In debates and discussions about vaccinations, it is easy to get caught up in the numbers and the percentages. A key job for MSPs is to scrutinise our Government on how it makes vaccines and boosters accessible to our constituents.
However, we know that the greater the delay in rolling out vaccines globally, the more people suffer. Right now, as Oxfam has pointed out in its campaign, the whole world is dependent on just a handful of pharmaceutical corporations, which simply cannot make enough vaccines for everyone.
As a country that, rightly, prides itself on the universality of our national health service, it is morally indefensible that we are not taking every possible action to waive the rules that are creating vaccine monopolies and allowing large pharmaceutical companies to profit off the back of a global pandemic.
In my motion, I note that monopolies are artificially limiting vaccine supply to low-income countries and that that vaccine inequality has resulted from a handful of pharmaceutical companies rationing supply by refusing to share their vaccine recipes and know-how with the rest of the world. That must end now.
As former Prime Minister Gordon Brown highlighted in The Guardian,
“In June, Boris Johnson promised he and the G7 countries would use their surplus vaccines to immunise the whole world. In September, at a summit chaired by President Biden, a December target of 40% vaccination was set for the 92 poorest countries. Two and a half months on, there is little chance of this target being met in at least 82 of them. By Thursday the US, which to its credit has been responsible for half the vaccines donated, had still delivered only 25% of the vaccines that it promised.”
The world is now living with the consequences of those broken promises.
It is not all doom and gloom. I welcome the fantastic work of the People’s Vaccine Alliance. Comprised of organisations that include Oxfam, Christian Aid, and Global Justice Now, the People’s Vaccine Alliance continues to advocate for fairness and an end to the vaccine inequalities.
I lodged a previous motion on this issue, which was similar to the one that we debate today. It gained the support of 55 members of the Scottish Parliament. To the First Minister’s credit, after it was lodged, she wrote to the Prime Minister to urge him to support the waiver.
However, one letter is not enough. I want to hear what work the Scottish Government is doing behind the scenes with United Kingdom Government colleagues and campaigners to ensure that those who are opposed to the waiver are challenged.
To the Conservatives in this Parliament I say, what work are you doing to communicate with colleagues in Westminster to get a different outcome?
In June, the European Parliament supported a temporary Covid-19 vaccine patent waiver. The vote was not unanimous but it reflected a strong agreement that action is urgently needed to produce affordable vaccines that can be distributed across the globe.
Evidence from the Covid-19 response so far and from many other public health issues throughout history, including the AIDS crisis in the 2000s, clearly illustrates that intellectual property rights restrict access. The situation will only get worse, unless Governments intervene.
The issue of high-priced medicines has become a global problem that affects not just low-income but middle and high-income countries. In the UK in the past few years, a breakthrough hepatitis C medicine has been rationed on the NHS, due to its high cost; cancer patients have had to crowd fund and campaign for treatments that have not been available on the NHS; and cystic fibrosis patients have had to wait more than three years to access a new therapy, as the pharmaceutical company priced the drug above the reach of our NHS.
Even though we have vaccines, in Scotland our NHS is under massive pressure from the pandemic. I ask colleagues to imagine what the Covid pressures look like in a low-income country with a small health budget and even fewer resources.
I again thank members for their support in securing this debate. I will continue to campaign on the need for political action and to focus on the concrete steps that we, through the Scottish Parliament and as individual MSPs, can take to bring vaccine equality globally.
We need a life-saving escalation in global vaccine production to ensure that people in low-income countries are kept safe. As I said, we are not safe until everyone is safe.